Phase I/II Study of the Combination of Dasatinib With Chemotherapy for High Risk Acute Myeloid Leukemia (AML) Patients
Phase of Trial: Phase I/II
Latest Information Update: 17 May 2018
Price : $35 *
At a glance
- Drugs Dasatinib (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 04 May 2018 Status changed from active, no longer recruiting to completed.
- 08 May 2017 Planned End Date changed from 1 Aug 2017 to 1 Apr 2018.
- 08 May 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Apr 2018.